Kura Oncology (KURA) Depreciation & Amortization (CF) (2014 - 2026)
Kura Oncology (KURA) reported Depreciation & Amortization (CF) of $355000.0 for Q1 2026, up 47.3% year-over-year from $241000.0 in Q1 2025, and down 11.91% quarter-over-quarter from $403000.0 in Q4 2025.
Kura Oncology (KURA) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $355000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $355000.0, up 47.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 42.01% YoY), and the FY2025 annual result was $1.0 million, up 29.0% from the prior year.
- Depreciation & Amortization (CF) eased to $355000.0 in Q1 2026 per KURA's latest filing, from $403000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $403000.0 in Q4 2025 and troughed at $156000.0 in Q4 2024.
- A 5-year average of $222764.7 and a median of $208000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) slumped 33.2% in 2023, then soared 158.33% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $247000.0 in 2022, then tumbled by 33.2% to $165000.0 in 2023, then declined by 5.45% to $156000.0 in 2024, then jumped by 158.33% to $403000.0 in 2025, then retreated by 11.91% to $355000.0 in 2026.
- Business Quant data shows KURA's Depreciation & Amortization (CF) at $355000.0 in Q1 2026, $403000.0 in Q4 2025, and $164000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | 355,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355,000.00 |
| Mar 31, 2026 | 355,000.00 |
| Dec 31, 2025 | 403,000.00 |
| Dec 31, 2025 | 403,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Jun 30, 2025 | 224,000.00 |
| Jun 30, 2025 | 224,000.00 |
| Mar 31, 2025 | 241,000.00 |
| Mar 31, 2025 | 241,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Sep 30, 2024 | 208,000.00 |
| Sep 30, 2024 | 208,000.00 |
| Jun 30, 2024 | 202,000.00 |
| Jun 30, 2024 | 202,000.00 |
| Mar 31, 2024 | 234,000.00 |
| Mar 31, 2024 | 234,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Dec 31, 2023 | 165,000.00 |